Does long term colchicine prevent degradation of collagen fiber network in osteoarthritis?

Aim Several studies have shown that colchicine exhibits an improvement in the symptoms of knee osteoarthritis (OA) but its effect on disease progression is unknown. To clarify the mechanism of action this study was done to see if colchicine prevents degradation of collagen fiber network in OA by stu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of rheumatic diseases 2018-01, Vol.21 (1), p.114-117
Hauptverfasser: Srivastava, Ragini, Das, Siddharth K., Goel, Gautam, Asthana, Akash, Agarwal, Girdhar G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim Several studies have shown that colchicine exhibits an improvement in the symptoms of knee osteoarthritis (OA) but its effect on disease progression is unknown. To clarify the mechanism of action this study was done to see if colchicine prevents degradation of collagen fiber network in OA by studying serum cartilage oligomeric matrix protein (COMP) levels, a marker of cartilage turnover, over a period of 1 year. Methods Seventy‐five patients received colchicine plus paracetamol and 75 received placebo alone for the same time period. Serum COMP assays were done at baseline, 2 months and 1 year by enzyme‐linked immunosorbent assay. These markers were compared between visits using repeated measures analysis of variance. Results Serum COMP levels in the paracetamol‐alone group did not show significant change between baseline and 2 months; however, there was a significant increase in serum COMP levels from 2 months to 1 year, suggesting increased uncoupling of proteoglycans from collagen and disease progression. No such change was seen in the colchicine group, signifying lack of progression of disease in this group. Conclusion Colchicine may act as a disease‐modifying agent in OA.
ISSN:1756-1841
1756-185X
DOI:10.1111/1756-185X.13022